Descemet Endothelial Thickness Comparison Trial II

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorStanford University

About this trial

Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Dysfunctional endothelium from FECD with few guttata extending beyond 4.5 mm

Peripheral endothelial cell count >1000 cells/mm2 in at least one quadrant

Good surgical candidate for either procedure as determined by the surgeon

Willingness to participate

Disqualifiers

Aphakia, anterior chamber IOL or scleral fixated IOL in study eye prior to or anticipated during EK

Pre-operative central sub-epithelial or stromal scarring that the investigator believes is visually significant and could impact post-operative stromal clarity assessment

Other primary endothelial dysfunction such as PPMD

Visually significant optic nerve or macular pathology

Trial design

Design model

Parallel

Treatments tested in this trial

  • Ripasudil

    Drug

    Topical Ripasudil 0.4%

  • Placebo

    Drug

    Topical Placebo

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: DMEK plus topical placeboPlacebo comparator 1 intervention
Group B: DSO plus topical ripasudil 0.4%Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Best spectacle-corrected visual acuity (BSCVA)

Best spectacle-corrected visual acuity (BSCVA)

Time frame
12 months

Secondary outcomes

1

Best spectacle-corrected visual acuity (BSCVA)

Best spectacle-corrected visual acuity (BSCVA)

Time frame
3, 6 and 24 months
2

Endothelial cell density

Endothelial cell density

Time frame
3, 6, and 24 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Stanford University

Lead sponsor

Oregon Health and Science University

Collaborator

University of California, San Francisco

Collaborator

University of California, Davis

Collaborator

Case Western Reserve University

Collaborator

Dartmouth-Hitchcock Medical Center

Collaborator

University of Pennsylvania

Collaborator

University of Miami

Collaborator

Wills Eye Hospital

Collaborator

Devers Eye Institute

Collaborator